CD22靶向CAR-T细胞疗法使CD19 CAR难治性大B细胞淋巴瘤获完全缓解
该研究报道了首3例自体CD19 CAR-T治疗难治的大B细胞淋巴瘤患者,接受单次输注1×10^6/kg CAR22 T细胞的I期剂量递增试验。CAR22耐受性较好,无>2级非血液学不良事件;3例均获完全缓解,末次随访(平均7.8个月,范围6–9.3)时均持续缓解,CAR22细胞扩增峰值85.4–350个/微升,>3个月仍可检测。
要点
- CD19 CAR-T难治性LBCL患者接受单次CAR22输注后3例均达完全缓解。
- 未观察到>2级非血液学不良事件,耐受性较好。
- CAR22细胞扩增峰值85.4–350个/微升,>3个月仍持续存在。
核心结论
- CD22靶向CAR-T可使CD19 CAR-T难治性大B细胞淋巴瘤患者获得完全缓解且耐受性较好。
研究设计与样本
- I期剂量递增研究,报道首3例连续的自体CD19 CAR-T难治性LBCL患者。
- 单次输注自体1×10^6/kg CAR+ T细胞靶向CD22。
主要发现
- 3例患者均达到完全缓解,末次随访时所有缓解持续(平均7.8个月,范围6–9.3)。
- 未观察到高于2级的非血液学不良事件。
- 循环CAR22细胞扩增峰值范围85.4–350个/微升,所有患者>3个月仍可检测。
- 输注后>6个月影像学持续缓解且循环肿瘤DNA相应下降。
关键数值与推荐
- CAR22单次输注剂量为1×10^6 CAR+ T细胞/kg。
- CAR22细胞扩增峰值范围85.4–350个/微升。
- 末次随访平均7.8个月(范围6–9.3),所有缓解持续。
临床怎么用
- 对于CD19 CAR-T治疗后进展的LBCL患者,可考虑CD22靶向CAR-T作为后续治疗选择。
- 治疗期间需监测CAR22细胞扩增及循环肿瘤DNA变化以评估疗效。
局限性
- 仅报道首3例患者,样本量小。
- 为I期剂量递增研究,更高剂量水平仍在入组中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of patients with large B-cell lymphoma (LBCL) that progresses after treatment with chimeric antigen receptor (CAR) T-cell therapy targeting CD19 (CAR19) is poor. We report on the first 3 consecutive patients with autologous CAR19-refractory LBCL who were treated with a single infusion of autologous 1 × 106 CAR+ T cells per kilogram targeting CD22 (CAR22) as part of a phase 1 dose-escalation study. CAR22 therapy was relatively well tolerated, without any observed nonhematologic adverse events higher than grade 2. After infusion, all 3 patients achieved complete remission, with all responses continuing at the time of last follow-up (mean, 7.8 months; range, 6-9.3). Circulating CAR22 cells demonstrated robust expansion (peak range, 85.4-350 cells per microliter), and persisted beyond 3 months in all patients with continued radiographic responses and corresponding decreases in circulating tumor DNA beyond 6 months after infusion. Further accrual at a higher dose level in this phase 1 dose-escalation study is ongoing and will explore the role of this therapy in patients in whom prior CAR T-cell therapies have failed. This trial is registered on clinicaltrials.gov as #NCT04088890.
引用
- Baird JH, Frank MJ, Craig J, et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood. 2021. PMID: 33512414. doi:10.1182/blood.2020009432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。